SOPHiA Genetics SA Dossier
Qualitative Analysis
Business overview
SOPHiA GENETICS SA (NASDAQ: SOPH) is a Swiss-American cloud-native software technology company pioneering data-driven medicine. The company's flagship offering is the SOPHiA DDM Platform, a decentralized, AI-native Software-as-a-Service (SaaS) platform that analyzes complex genomic, radiomic, and clinical multimodal datasets. By translating raw biological data into real-time, actionable clinical insights, SOPHiA DDM serves as a universal operating system for precision medicine, supporting over 990 hospitals, laboratories, and biopharma institutions globally in diagnosing and treating cancer and rare disorders.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Integrating the SOPHiA DDM platform into laboratory workflows of major U.S. healthcare systems, including a top nonprofit multi-region integrated system and a top 10 U.S. health system laboratory, to launch genomic testing for up to 60,000 patients annually.
Expected impact: Substantially increases clinical genomics analysis volume in North America and establishes a scalable foundation for future precision medicine applications.
Implementing validated near-term science-based greenhouse gas emissions reduction targets, including a commitment to reduce absolute Scope 2 GHG emissions by 42.0% by 2030 from a 2024 base year, and measuring Scope 3 emissions.
Expected impact: Aligns corporate operations with the Paris Agreement decarbonization pathways and enhances ESG compliance for institutional investors.
Collaborating with BioPharma partners on evidence generation, sponsored deployment projects, and the co-development of future companion diagnostic offerings utilizing the SOPHiA DDM platform.
Expected impact: Diversifies revenue streams beyond clinical customers and establishes long-term high-margin pharmaceutical partnerships.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Aims to form a joint venture to establish a precision medicine hub combining MSK's clinical data and oncology expertise with SOPHiA GENETICS' AI platform to discover, develop, and deploy next-generation precision oncology solutions globally.
Terms: Specific financial terms of the joint venture are yet to be finalized under the signed Memorandum of Understanding.
Combines SOPHiA GENETICS' decentralized SOPHiA DDM platform with Strand's curated variant databases and bioinformatics expertise to collaborate on strategic test co-development and expand precision medicine access globally, particularly in India.
Terms: Collaborative test co-development and mutual platform integration terms.
Partnered to bring blood-based cancer testing (liquid biopsy) to patients across the United Kingdom, leveraging the SOPHiA DDM platform to improve clinical workflows and turnaround times.
Terms: Commercial platform usage and analysis-based pricing terms.